BRIEF—Glenmark launches Akynzeo IV in India

Indian drugmaker Glenmark Pharmaceuticals today announced it is the first to launch in India a unique intravenous (IV) injection formulation, Akynzeo IV, a fixed dose combination of fosnetupitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV), under an exclusive licensing agreement with privately-held Swiss drugmaker Helsinn.

Helsinn Group chief executive, Giorgio Calderari, said: “Akynzeo IV would provide a new prophylactic option for patients in India, undergoing chemotherapy and who are at risk of CINV. We are delighted to partner with Glenmark who has an excellent footprint in this region and is trusted with providing the best treatment options for cancer patients.”

In 2018, Glenmark revolutionized cancer supportive care in the country by launching Akynzeo oral capsules, the first and only CINV prevention therapy to prevent both acute and delayed phases of CINV by a single dose.